Lexicon Pharmaceuticals

At the H.C. Wainwright conference, Lexicon Pharmaceuticals presented a focused cardiometabolic strategy and placed sotagliflozin at the center of its near-term plans. The company expects top-line data from the Phase III SONATA-HCM study in Q1 2027 and is planning a possible resubmission to the FDA for type 1 diabetes in Q4 2026. Lexicon is expanding pre-commercial activities, reported milestone payments from Novo Nordisk for the obesity program LX9851, and emphasized operational discipline and support from partnerships with Novo Nordisk and Viatris. » More on de.investing.com

At the Leerink conference, Lexicon Pharmaceuticals set its strategic focus on cardiometabolic diseases and chronic pain, prioritizing late‑stage programs. The company plans a resubmission of the NDA for Zynquista in type 1 diabetes, the SONATA Phase‑3 study of sotagliflozin in HCM will complete recruitment by midyear, and a Phase‑3 design for pilavapadin in DPNP has been agreed with positive FDA feedback. The partnership with Novo Nordisk for LX9851 has hit milestones (USD 10 million) with further payments possible, while regulatory approval risks and competitive pressure remain key challenges. » More on de.investing.com

Lexicon Pharmaceuticals reported Q4 2025 EPS of -$0.04 (expected -$0.07) and revenue of $5.5 million versus projected $3.92 million. The company sharply cut R&D and SG&A expenses and significantly improved its net loss year over year. Despite the stronger metrics, the stock fell about 4.3% in premarket trading. For 2026, Lexicon expects total operating costs of $100–$110 million and is focusing investments on its cardiometabolic platform, including sotagliflozin and a resubmission for Zynquista. » More on de.investing.com

Lexicon Pharmaceuticals completed a public offering and a concurrent private placement, raising about $100 million. In the public offering, 32 million common shares were sold at $1.30 per share; in addition, investors placed 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 each. The proceeds are intended to fund research and development, working capital and general corporate purposes and strengthen the balance sheet, although the company continues to show negative EBITDA and gross margins; the liquidity metric remains high with a current ratio of 5.64. » More on de.investing.com

Lexicon Pharmaceuticals shares dropped about 14.9% after the pricing was announced for a public offering of 32 million common shares at $1.30 each (gross proceeds about $41.6 million). At the same time, a private placement to an affiliate of Invus is underway for 22.4 million common shares at $1.30 and Series B convertible preferred shares at $65, including a buyer option on additional preferred shares that could generate roughly $11.9 million in additional proceeds. Closing is expected under customary conditions on Feb. 2, 2026; net proceeds are intended to fund research and development, working capital and general corporate purposes. » More on de.investing.com